P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir.

Abstract:

BACKGROUND:Drug efflux (for example, P-glycoprotein [P-gp], multidrug resistance-associated proteins [MRPs] and breast cancer resistance protein [BCRP]) and influx (for example, human organic anion transporting polypeptide [hOCTP] or human organic anion transporting polypeptide [hOATP]) transporters alter the cellular concentrations of some HIV protease inhibitors (HPIs). Here, we studied the lipophilicity and uptake of [(3)H]-atazanavir (ATV) in CEM (parental), CEM(VBL) (P-gp-overexpressing), CEM(E1000) (MRP1-overexpressing) and peripheral blood mononuclear cells (PBMCs), and evaluate the effects of modulators of drug transporters on uptake. METHODS:Lipophilicity was measured by octanol/saline partition method. The influence of influx/efflux transporters on uptake was evaluated in the absence and presence of inhibitors of P-gp (GPV031), P-gp/BCRP (tariquidar and GF120918), P-gp/MRP1 (dipyridamole and daidzein), MRP1/2 (frusemide and genistein), hOATP/hOCTP (estrone-3-sulfate [E-3-S]) and hOATP/hOCTP/MRP (probenecid). The effects of a number of HPIs on uptake were also evaluated. Data from digitonin permeabilized cells allowed the evaluation of the contribution of cellular binding to total drug uptake, whereas the inhibitory effect of ATV on P-gp was assessed by daunomycin efflux/uptake assays. RESULTS:[(3)H]-ATV is lipophilic and accumulates in the cultured cells as follows: CEM>CEM(E1000)>CEM(VBL). Tariquidar, GF120918 and daidzein significantly increased the uptake of [(3)H]-ATV in the cultured cells. By contrast, only daidzein and tipranavir significantly increased uptake in PBMCs, with tariquidar and frusemide devoid of effects, whereas dipyridamole, E-3-S, GPV031 and genistein significantly decreased accumulation. ATV inhibits P-gp activity; manipulation of uptake with digitonin suggests binding of [(3)H]-ATV to P-gp. CONCLUSIONS:[(3)H]-ATV is lipophilic, a P-gp, MRP and hOATP substrate and an inhibitor of P-gp. Concomitant administration of ATV with drugs and dietary components (for example, daidzein and genistein) that interact with these transporters could alter its pharmacokinetics.

journal_name

Antivir Ther

journal_title

Antiviral therapy

authors

Janneh O,Anwar T,Jungbauer C,Kopp S,Khoo SH,Back DJ,Chiba P

doi

10.3851/IMP1399

subject

Has Abstract

pub_date

2009-01-01 00:00:00

pages

965-74

issue

7

eissn

1359-6535

issn

2040-2058

journal_volume

14

pub_type

杂志文章
  • Anaemia is associated with monocyte activation in HIV-infected adults on antiretroviral therapy.

    abstract:BACKGROUND:Anaemia has been linked with mortality in HIV infection. The mechanism of anaemia in the era of contemporary antiretroviral therapy is not understood. The aim of this study was to describe the association between anaemia and markers of immune activation and inflammation in a cohort of HIV-infected adults on ...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.3851/IMP2940

    authors: Lipshultz HM,Hileman CO,Ahuja S,Funderburg NT,McComsey GA

    更新日期:2015-01-01 00:00:00

  • Targeting human papillomavirus genome replication for antiviral drug discovery.

    abstract::Human papillomavirus (HPV) infections are a major human health problem; they are the cause of recurrent benign warts and of several cancers of the anogenital tract and head and neck region. Although there are two prophylactic HPV vaccines that could, if used universally, prevent as many as two-thirds of HPV-induced ca...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP2612

    authors: Archambault J,Melendy T

    更新日期:2013-01-01 00:00:00

  • Zidovudine treatment is not associated with HTLV-1 reverse transcriptase gene mutations in HTLV-I/HIV-1 co-infected patients.

    abstract::Zidovudine treatment of human immunodeficiency virus (HIV) infection induces drug-resistant viral strains harbouring specific amino acid substitutions in the reverse transcriptase (RT). To investigate whether this phenomenon could be observed in the case of human T lymphotropic virus type I (HTLV-I) infection, we anal...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Gasmi M,Fillon S,Leriche K,Neisson-Vernant C,Desgranges C

    更新日期:1997-04-01 00:00:00

  • Experience with nevirapine in previously treated HIV-1-infected individuals.

    abstract:OBJECTIVE:To assess the tolerability, virological, immunological and clinical effects of nevirapine in the setting of a compassionate use programme in pretreated HIV-infected individuals. DESIGN:Retrospective observational cohort-study in 13 HIV-outpatient clinics in The Netherlands. METHODS: MAIN OUTCOME MEASURES:p...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Wit FW,Dutch HIV-treating physicians.

    更新日期:2000-12-01 00:00:00

  • A light in the cognitive fog?

    abstract::HIV escape in the central nervous system (CNS) despite undetectable viral load in the plasma has been observed and may contribute to HIV-associated neurocognitive disorders. Favouring the use of HIV drugs with a good penetration into the CNS has been advocated, leading to the establishment of the CNS penetration-effec...

    journal_title:Antiviral therapy

    pub_type: 评论,杂志文章

    doi:10.3851/IMP2561

    authors: Cavassini M,Du Pasquier RA

    更新日期:2013-01-01 00:00:00

  • Long-term lamivudine treatment is associated with a good maintained response in severe acute exacerbation of chronic HBeAg-negative hepatitis B.

    abstract::Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B is difficult to treat and there is little long-term data for lamivudine treatment of severe acute exacerbation. We report a prospective, consecutive cohort of severe acute exacerbation of HBeAg-negative chronic hepatitis B patients treated by lamivudine betwee...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章

    doi:

    authors: Chan HL,Wong VW,Hui AY,Tsang SW,Chan JL,Chan HY,Wong GL,Sung JJ

    更新日期:2006-01-01 00:00:00

  • Prevalence and clinical implications of insertions in the HIV-1 p6Gag N-terminal region in drug-naive individuals initiating antiretroviral therapy.

    abstract::We assessed the prevalence and clinical impact of insertions within the HIV-1 p6Gag proline-rich (PTAP) region on initial antiretroviral therapy response in 461 HIV-infected, drug-naive individuals initiating therapy in British Columbia, Canada between June 1996 and August 1998. HIV p6Gag insertions were detected by n...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Brumme ZL,Chan KJ,Dong WW,Wynhoven B,Mo T,Hogg RS,Montaner JS,O'Shaughnessy MV,Harrigan PR

    更新日期:2003-04-01 00:00:00

  • The impact of ribavirin plasma concentration on the efficacy of the interferon-sparing regimen, sofosbuvir and ribavirin.

    abstract:BACKGROUND:Ribavirin augments sustained virological response when administered with pegylated interferon for the treatment of chronic HCV infection. The impact of ribavirin plasma concentration on outcome in individuals receiving interferon-free regimens has not been evaluated. METHODS:Stored plasma samples were retri...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2984

    authors: Martinello M,Schteinman A,Alavi M,Williams K,Dore GJ,Day R,Matthews GV

    更新日期:2016-01-01 00:00:00

  • Therapeutic drug monitoring of antiretroviral drugs at home using dried blood spots: a proof-of-concept study.

    abstract:BACKGROUND:In HIV-infected patients, therapeutic drug monitoring (TDM) of antiretroviral drugs is recommended in special populations and in specific situations to optimize therapy. Currently, TDM is performed via measurement of drug plasma concentrations; however, dried blood spots (DBS) may offer a patient friendly an...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2501

    authors: Kromdijk W,Mulder JW,Smit PM,Ter Heine R,Beijnen JH,Huitema AD

    更新日期:2013-01-01 00:00:00

  • Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001.

    abstract:BACKGROUND:The emergence of human monkeypox and the potential use of recombinant variola and monkeypox viruses as biological terrorist agents have necessitated the development of therapeutic and prophylactic therapies. The primary, or index, cases of smallpox and/or human monkeypox will likely be identified by a charac...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Parker S,Schriewer J,Oberle C,Robertson A,Lanier R,Painter G,Buller RM

    更新日期:2008-01-01 00:00:00

  • HIV-1 genital shedding in HIV-infected patients randomized to second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir.

    abstract:BACKGROUND:HIV-1 shedding in genital secretions is associated with HIV transmission risk. Limited data exist on the effect of second-line lopinavir/ritonavir monotherapy (mLPV/r) on genital secretion of HIV RNA. METHODS:We measured HIV-1 in genital secretions of HIV-infected adults at time of failure from non-nucleosi...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章

    doi:10.3851/IMP2737

    authors: Bunupuradah T,Bowonwattanuwong C,Jirajariyavej S,Munsakul W,Klinbuayaem V,Sophonphan J,Mahanontharit A,Hirschel B,Ruxrungtham K,Ananworanich J,HIV STAR Study team.

    更新日期:2014-01-01 00:00:00

  • Management of multidrug-resistant CMV infection in immunocompromised patients: case report of a heart-transplant recipient and review of the literature.

    abstract::Cytomegalovirus (CMV) remains a leading cause of morbidity after solid organ transplantation. The efficiency of antivirals for the treatment of CMV infections may be hampered because of the emergence of CMV resistance to antivirals. The development of CMV multidrug resistance, which remains uncommon but does occur, co...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP2818

    authors: Deback C,Burrel S,Varnous S,Carcelain G,Conan F,Aït-Arkoub Z,Autran B,Gandjbakhch I,Agut H,Boutolleau D

    更新日期:2015-01-01 00:00:00

  • HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B.

    abstract::Although chronic HBV infection is the leading cause of chronic liver disease and death worldwide, there are substantial differences in its clinical courses regarding prevalence, mode of transmission, characteristics of each phase, responses to antiviral therapy, and development of cirrhosis and hepatocellular carcinom...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP1982

    authors: Kim BK,Revill PA,Ahn SH

    更新日期:2011-01-01 00:00:00

  • Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection.

    abstract::There is a need for new antiretroviral drugs with activity against HIV isolates resistant to currently available agents and improved short and long-term tolerability profiles. Clinical trial designs for nucleotide and nucleoside reverse transcriptase inhibitors (NRTIs) are restricted by the characteristics of these ag...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:

    authors: Wainberg MA,Sawyer JP,Montaner JS,Murphy RL,Kuritzkes DR,Raffi F

    更新日期:2005-01-01 00:00:00

  • Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients.

    abstract:BACKGROUND:Suboptimal doses of ribavirin have been suggested to explain the diminished efficacy of pegylated interferon (PEG-IFN) plus ribavirin in hepatitis C virus (HCV)-HIV-coinfected patients. METHODS:A cohort of 104 coinfected patients and an age-, sex- and genotype-matched cohort of HCV-monoinfected patients (n ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Tural C,Galeras JA,Planas R,Coll S,Sirera G,Giménez D,Salas A,Rey-Joly C,Cirera I,Márquez C,Tor J,Videla S,García-Retortillo M,Clotet B,Solà R

    更新日期:2008-01-01 00:00:00

  • Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir.

    abstract:BACKGROUND:The objective of this study was to compare indinavir peak plasma (Cmax) values after administration of indinavir/ritonavir 800/100 mg on an empty stomach or with food. High indinavir Cmax values have been associated with indinavir-related nephrotoxicity. METHODS:This was an open-label, randomized, two-treat...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Aarnoutse RE,Wasmuth JC,Fätkenheuer G,Schneider K,Schmitz K,de Boo TM,Reiss P,Hekster YA,Burger DM,Rockstroh JK

    更新日期:2003-08-01 00:00:00

  • Impact of CCR5, integrase and protease inhibitors on human endothelial cell function, stress, inflammation and senescence.

    abstract:BACKGROUND:Ageing HIV-infected patients present an increased incidence of cardiovascular diseases, endothelial dysfunction being an early alteration. Some protease inhibitors (PIs) have been shown to increase the risk of cardiovascular disease. We evaluated here the effects of CCR5 or integrase inhibitors as compared t...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3160

    authors: Afonso P,Auclair M,Caron-Debarle M,Capeau J

    更新日期:2017-01-01 00:00:00

  • Cidofovir does not prevent caprine herpesvirus type-1 neural latency in goats.

    abstract:BACKGROUND:Cidofovir (CDV) is an acyclic nucleoside phosphonate that exhibits a potent antiviral activity against several DNA viruses. In previous studies, CDV has been shown to significantly reduce the clinical severity and the viral shedding in primary caprine herpesvirus type-1 (CpHV-1) infection in goats. CpHV-1 is...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1611

    authors: Camero M,Crescenzo G,Marinaro M,Tarsitano E,Bellacicco AL,Armenise C,Buonavoglia C,Tempesta M

    更新日期:2010-01-01 00:00:00

  • Patients' preferences regarding the timing of highly active antiretroviral therapy initiation for chronic asymptomatic HIV-1 infection.

    abstract:OBJECTIVE:In patients with a chronic asymptomatic HIV-1 infection and >200 CD4+ T-cells/microl, the optimal timing of highly active antiretroviral therapy (HAART) initiation is unclear. It involves a trade-off between a potentially reduced risk of mortality, when started earlier in the course of infection, and an earli...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Locadia M,van Grieken RA,Prins JM,de Vries HJ,Sprangers MA,Nieuwkerk PT

    更新日期:2006-01-01 00:00:00

  • HIV-associated neurocognitive disorders and central nervous system drug penetration: what next?

    abstract::The current prevalence of cognitive impairment in HIV-infected individuals is surprisingly high, even in those with undetectable plasma HIV RNA. The aetiology is unknown but one possibility is inadequate control of persistent central nervous system (CNS) HIV infection. The CNS Penetration Effectiveness (CPE) rank has ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2951

    authors: Marra CM

    更新日期:2015-01-01 00:00:00

  • The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir.

    abstract::Boceprevir and telaprevir are peptidomimetic serine protease inhibitors that have been recently approved for the treatment of HCV chronic infection. The addition of these drugs to the prior standard of care, pegylated interferon and ribavirin, improves sustained virological response rates for treatment-naive and treat...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP2424

    authors: Marks KM,Jacobson IM

    更新日期:2012-01-01 00:00:00

  • Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database.

    abstract:BACKGROUND:Nucleoside reverse transcriptase inhibitor (NRTI)-associated mutations (NAMs) can affect response to treatment with NRTIs and might also result in HIV-1 with reduced replication capacity. METHODS:A large commercial HIV-1 database (n=60,487) was analysed for the prevalence of NAMs, antiviral drug susceptibil...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: McColl DJ,Chappey C,Parkin NT,Miller MD

    更新日期:2008-01-01 00:00:00

  • Do we need genotypic weighted resistance scores for antiretrovirals? The curious case of tipranavir.

    abstract::Weighted genotypic resistance scores represent a step towards excellence in the interpretation of HIV type-1 (HIV-1) resistance to antiretroviral drugs. They can predict phenotypic resistance and clinical response better than any other unweighted score. With the addition of mutations associated with an increased respo...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1671

    authors: Llibre JM

    更新日期:2010-01-01 00:00:00

  • Early antiretroviral therapy: rationale, protease inhibitor-sparing regimens and once daily dosing.

    abstract::In 1998 it seems reasonable and widely accepted that all human immunodeficiency virus type 1 (HIV-1)-infected patients willing to be treated may benefit from receiving antiretroviral therapy. Only those with undetectable plasma HIV-1 RNA, normal CD4 lymphocyte counts and lack of markers of immunological system activat...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:

    authors: Gatell JM

    更新日期:1998-01-01 00:00:00

  • Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response.

    abstract:BACKGROUND:Rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), was approved for HIV-1 infected, antiretroviral treatment-naive adults based on data from two Phase III trials. In the screening population, the prevalence of 49 NNRTI resistance-associated mutations (RAMs) and the impact of allowed...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,随机对照试验

    doi:10.3851/IMP2358

    authors: Vingerhoets J,Rimsky L,Van Eygen V,Nijs S,Vanveggel S,Boven K,Picchio G

    更新日期:2013-01-01 00:00:00

  • Pharmacokinetics and safety in cynomolgus monkeys of a monoclonal antibody targeting human scavenger receptor class B type-1 for hepatitis C treatment.

    abstract:BACKGROUND:Scavenger receptor class B type-1 (SR-B1) is one of the many receptors used by HCV to infect hepatocytes. It is used by the virus not only to directly infect cells but also to facilitate cell-to-cell transmission of the virus. Agents such as anti-human SR-B1 (anti-hSR-B1) antibodies represent potential thera...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2570

    authors: Flores MV,Corbau RG,Guionaud S

    更新日期:2013-01-01 00:00:00

  • Antiretoviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis.

    abstract::Clinical research has indicated that the use of nucleoside reverse transcriptase inhibitor (NRTI) and HIV protease inhibitor (PI) therapy is associated with a risk of long-term toxicity syndromes, and that the aetiopathogenesis of these adverse effects is independent of the antiretroviral effects of these drugs. In re...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:

    authors: Nolan D,John M,Mallal S

    更新日期:2001-09-01 00:00:00

  • Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir.

    abstract:BACKGROUND:Among 141 HIV-HBV-coinfected patients treated with tenofovir in our centre, 87% were good-responders to therapy. Seven patients showed a delayed response to tenofovir. The present study was performed to evaluate the quasispecies variability and the in vitro drug susceptibility to approved antiviral drugs of ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1940

    authors: Lada O,Gervais A,Branger M,Peytavin G,Roquebert B,Collin G,Fraqueiro G,Moucari R,Leclerc L,Martinot-Peignoux M,Matheron S,Marcellin P

    更新日期:2012-01-01 00:00:00

  • Predictive value of codon 215 reverse transcriptase mutation on the efficacy of didanosine in HIV-infected, zidovudine-experienced patients.

    abstract::We investigated whether or not mutations at codon 215 in the HIV reverse-transcriptase-encoding gene predicted a lower efficacy of didanosine therapy, as defined by survival of patients and change in CD4 cell counts in 121 HIV-infected, zidovudine-experienced patients. A trend for shorter survival, although not reachi...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Yerly S,Denereaz N,Mermillod B,Hirschel B,Perrin L

    更新日期:1996-08-01 00:00:00

  • Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods.

    abstract::Infection with influenza viruses, including seasonal, avian and pandemic viruses, remains a worldwide public health problem. Although influenza virus infection is both vaccine preventable and drug treatable, high rates of mutation and reassortment of viruses can result in reduced effectiveness of vaccines or drugs. Cu...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP2067

    authors: Nguyen HT,Fry AM,Gubareva LV

    更新日期:2012-01-01 00:00:00